萊茵生物:就美國工業大麻提取及應用工程建設項目簽訂工廠設計建造合同
格隆匯2月10日丨萊茵生物(002166.SZ)公佈,誠如之前公告披露,公司擬在美國投資5818.1萬美元建設“工業大麻提取及應用工程建設項目”。該事項已經公司第五屆董事會第十五次會議、2019年第2次臨時股東大會審議通過,並已於2019年10月取得廣西壯族自治區商務廳頒發的《企業境外投資證書》(境外投資證第N4500201900057號),於2019年12月完成了項目用地的購買和交割。
近日,在公司2019年第2次臨時股東大會的授權下,公司的全資子公司HEMPRISE,LLC(與公司及下屬子公司統稱“業主”)與Gray Construction,Inc.(“Gray”、“設計施工方”)簽訂了《STANDARD DESIGN-BUILD AGREEMENT AND GENERAL CONDITIONS BETWEEM OWNER AND DESIGN-BUILDER》(標準設計建造合同,“合同”)以及相關附件,合同金額總價約3000萬美元,若雙方按合同約定對工程內容進行變更的,合同金額可按合同的規定進行調整。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.